Who are Finacea's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Avodart, Azelex, Gamolenic, Avodart.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/finacea.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Finacea — Competitive Intelligence Brief

Finacea (Finacea) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Dermatology.

marketed 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Finacea (Finacea) — Actavis Inc..

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Finacea TARGET	Finacea	Actavis Inc.	marketed		3-oxo-5-alpha-steroid 4-dehydrogenase 2
Avodart	dutasteride	GSK (GlaxoSmithKline)	marketed	5-alpha-reductase inhibitor (dual)	3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1	2001-11-20
Azelex	AZELAIC ACID	Leo Pharma As	marketed	azelaic acid	3-oxo-5-alpha-steroid 4-dehydrogenase 2	1995-01-01
Gamolenic	GAMOLENIC ACID		marketed	gamolenic acid	Free fatty acid receptor 1, Peroxisome proliferator-activated receptor delta, 3-oxo-5-alpha-steroid 4-dehydrogenase 2
Avodart	Avodart	GlaxoSmithKline	marketed		3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-09-18 — Azelex · 7700076 · Formulation · US
2027-10-18 — Azelex · 10117812 · Formulation · US
2027-12-08 — Azelex · 9265725 · Formulation · US
2029-02-28 — Azelex · 9211259 · Method of Use · US

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Finacea — Competitive Intelligence Brief. https://druglandscape.com/ci/finacea. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab